Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.

abstract：:Progress in chronic lymphocytic leukemia (CLL) therapies has extended greatly the length and depth of remission, with the goal of treatment advancing towards a cure for some patients. Accordingly, clinical endpoints must evolve to capture these outcomes, and to provide faster access to novel therapies. Minimal residua...

journal_title：Leukemia & lymphoma

authors： Owen C,Christofides A,Johnson N,Lawrence T,MacDonald D,Ward C

更新日期：2017-12-01 00:00:00

abstract：:The relationship between histopathologic characteristics and treatment outcomes in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab-based immunochemotherapy needs re-evaluation. Patients with newly diagnosed DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...

journal_title：Leukemia & lymphoma

authors： Hong J,Park S,Park J,Kim HS,Kim KH,Ahn JY,Rim MY,Jung M,Sym SJ,Cho EK,Shin DB,Lee JH

更新日期：2011-10-01 00:00:00

abstract：:A 26-year-old man with a history of common variable immunodeficiency and Evans syndrome (immunthrombocytopenia and immunhemolytic anemia) with sarcoid like lesions and lymph node enlargements in the previous history is described. The patient presented with symptoms resembling Guillain-Barre-Strohl as paraneoplastic sy...

journal_title：Leukemia & lymphoma

authors： Mailänder V,Gleisner B,Blau IW,Thiel E

更新日期：2004-01-01 00:00:00

abstract：:Successful peripheral blood stem cell (PBSC) collection depends on the timing of apheresis based on CD34+ cell enumeration. Because this analysis is expensive and induces organization difficulties, we evaluated hematopoietic progenitor cell (HPC) quantification on the Sysmex XE-2100 as a surrogate analysis. We tested ...

journal_title：Leukemia & lymphoma

authors： Letestu R,Marzac C,Audat F,Belhocine R,Tondeur S,Baccini V,Garçon L,Cortivo LD,Perrot JY,Lefrère F,Valensi F,Ajchenbaum-Cymbalista F

更新日期：2007-01-01 00:00:00

abstract：:This single institution cohort study of 132 AML patients investigated the clinical implications of co-mutations detected with a 42-gene NGS panel. In the intermediate-risk cytogenetic group, FLT3-ITD is an adverse prognostic indicator only in the presence of a DNMT3A co-mutation, regardless of NPM1 mutation status. In...

journal_title：Leukemia & lymphoma

authors： Ma J,Dunlap J,Paliga A,Traer E,Press R,Shen L,Fan G

更新日期：2018-08-01 00:00:00

abstract：:The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

journal_title：Leukemia & lymphoma

authors： Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

更新日期：2019-12-01 00:00:00

abstract：:We evaluated the prognostic role of 18FDG-PET performed before ASCT in patients affected by lymphoma who underwent high-dose chemotherapy followed by ASCT as first-line treatment for high-risk disease or as second-line or more for relapsed or refractory disease. We retrospectively analyzed 53 consecutive patients, 14 ...

journal_title：Leukemia & lymphoma

authors： Crocchiolo R,Canevari C,Assanelli A,Lunghi F,Tassara M,Stanghellini ML,Clerici D,Landoni C,Servida P,Bernardi M,Peccatori J,Ferreri A,Gianolli L,Bordignon C,Caligaris-Cappio F,Ciceri F,Fazio F

更新日期：2008-04-01 00:00:00

abstract：:In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance. Here we report the first multicenter Argentinean study investigating mutations in those patients with CML who fail or lose response to imatinib, with or without previous interferon treatment...

journal_title：Leukemia & lymphoma

authors： Bengió RM,Riva ME,Moiraghi B,Lanari E,Milone J,Ventriglia V,Bullorsky E,Tezanos Pinto Md,Murro H,Bianchini M,Larripa I

更新日期：2011-09-01 00:00:00

abstract：:Peripheral lymphopenia is a well-known negative prognostic marker in classical Hodgkin lymphoma (cHL). We characterized the peripheral B-cell compartment in a prospective cohort of 83 pediatric cHL patients. We observed significantly low total B-cell counts (<100 cells/µl) in 31 of 83 patients (37%). More specifically...

journal_title：Leukemia & lymphoma

authors： Hamdi L,Creidy R,Boudjemaa S,Hendel-Chavez H,Hugues P,Taoufik Y,Leblanc T,Coulomb A,Krzysiek R,Landman-Parker J,Besson C

更新日期：2020-10-23 00:00:00

abstract：:We conducted a population-based study to assess how positron emission tomography (PET) is currently used in patients with Hodgkin lymphoma (HL). Four cancer registries from northern Italy were used to identify patients with HL diagnosed from 2006 to 2008. Computed tomography (CT) and PET scans were collected before tr...

journal_title：Leukemia & lymphoma

authors： Luminari S,Cesaretti M,Tomasello C,Guida A,Bagni B,Merli F,Postiglione R,Mangone L,Versari A,Re F,De Lisi V,Ruffini L,Ferretti S,Cuneo A,Federico M

更新日期：2011-09-01 00:00:00

abstract：:HMG-CoA Reductase inhibitors (statins) induce apoptosis in acute myeloid leukemia (AML) cells in vitro; however, the concentrations associated with cell death in AML cells are higher than those clinically tolerated during prolonged therapy. We therefore wished to determine whether short exposures to lovastatin might i...

journal_title：Leukemia & lymphoma

authors： Burke LP,Kukoly CA

更新日期：2008-02-01 00:00:00

abstract：:The aim of this study was to assess the immunogenic potential of irradiated lymphoma cells in vivo and determine whether immunogenicity can be enhanced by modulation of the host immune system. Syngeneic murine lymphoma models irradiated ex vivo were used as an orthotopic cellular vaccination prior to challenge with vi...

journal_title：Leukemia & lymphoma

authors： Honeychurch J,Melis MH,Dovedi SJ,Mu L,Illidge TM

更新日期：2013-09-01 00:00:00

abstract：:Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 10(9)/L not reached by day + 28 afte...

journal_title：Leukemia & lymphoma

authors： Ferrà C,Sanz J,Díaz-Pérez MA,Morgades M,Gayoso J,Cabrera JR,Villaescusa T,Sampol MA,Fernández-Avilés F,Solano C,Ortín M,Duarte R,Cuesta M,Heras I,de la Serna J,Moraleda JM,Barrenetxea C,González-Vicent M,Sanz G,Ribe

更新日期：2015-03-01 00:00:00

abstract：:The objective of this work was to determine the safety and efficacy of gemtuzumab ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the following diagnoses/characteristics were treated with 1-3 infusions of gemtuzumab ozogamicin at a dose of 9 mg/m2: (1) relapse of AML < or = 6 mon...

journal_title：Leukemia & lymphoma

authors： Roboz GJ,Knovich MA,Bayer RL,Schuster MW,Seiter K,Powell BL,Woodruff RD,Silver RT,Frankel AE,Feldman EJ

更新日期：2002-10-01 00:00:00

abstract：:Obesity is a risk factor for mortality and relapse of certain cancers. However, existing evidence for pediatric leukemia is inconsistent. The aim of this systematic review and meta-analysis was to evaluate the association between obesity at diagnosis and pediatric acute leukemia mortality and relapse. This study syste...

journal_title：Leukemia & lymphoma

authors： Amankwah EK,Saenz AM,Hale GA,Brown PA

更新日期：2016-05-01 00:00:00

abstract：:The standard of therapy for the high risk adult neutropenic host being treated with broad spectrum antibiotics for fever has been to continue intravenous antibiotics until neutropenia resolves. We performed a small, limited pilot study to determine if it is safe to switch these patients to oral monotherapy with ciprof...

journal_title：Leukemia & lymphoma

authors： Horowitz HW,Holmgren D,Seiter K

更新日期：1996-09-01 00:00:00

abstract：:Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding V(H) and V(L)...

journal_title：Leukemia & lymphoma

authors： Stevenson FK,King A,Ottensmeier CH

更新日期：2003-01-01 00:00:00

abstract：:The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway is active in both normal hematopoiesis and hematological malignancies. Moreover, Janus kinase-2 (JAK2) is the key hematopoietic kinase, and mutations together with single nucleotide polymorphisms (SNPs) of JAK2 have been thoroughly ev...

journal_title：Leukemia & lymphoma

authors： Zhong Y,Chen B,Feng J,Cheng L,Li Y,Qian J,Ding J,Gao F,Xia G,Chen N,Lu Z

更新日期：2010-06-01 00:00:00

abstract：:Phosphorylation of p27(Kip1) at threonine 187 (pThr187-p27(Kip1)) occurs frequently in the development of human tumors, directing protein polyubiquitination and subsequent proteasomal degradation. We investigated the immunoexpression of p27(Kip1) and pThr187-p27(Kip1) in 126 B-cell lymphomas and their relation to prol...

journal_title：Leukemia & lymphoma

authors： Sirinian C,Symeonidis A,Giannakoulas N,Zolota V,Melachrinou M

更新日期：2011-05-01 00:00:00

abstract：:The insulin-like growth factor (IGF) system regulates proliferation and differentiation of hematopoietic cells. IGFs exert their effects through specific receptors on growing and differentiating blood cells as they emerge from their small pool of ancestral stem cells. The IGF system is complex as both stimulating and ...

journal_title：Leukemia & lymphoma

authors： Zumkeller W

更新日期：2002-03-01 00:00:00

abstract：:Relative risks of treatment-emergent adverse events (TEAEs) and related hospitalization is most accurate when accounting for treatment exposure. AZA-AML-001 showed azacitidine (AZA) prolonged overall survival versus conventional care regimens (CCR) in older patients (≥65 years) with acute myeloid leukemia (AML) by 3.9...

journal_title：Leukemia & lymphoma

authors： Seymour JF,Döhner H,Minden MD,Stone R,Gambini D,Dougherty D,Beach CL,Weaver J,Dombret H

更新日期：2017-06-01 00:00:00

abstract：:Binding of Fas ligand (FasL) or an agonistic anti-Fas receptor (Fas/CD95) antibody induces apoptosis in Fas-bearing target cells. The involvement of Fas/FasL pathway has been investigated in human acute myelogenous leukemia (AML) cells. Fas/CD95 is expressed on a majority of AML cells, although the intensity of expres...

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1997-03-01 00:00:00

abstract：:The expression of the interleukin 2 (IL2) receptor chains was investigated by immunofluorescence and mRNA analysis in typical and variant hairy cell leukemia (HCL) cases. While typical hairy cells express both the alpha and the beta chains, variant HCL express the IL2 receptor beta chain on the surface membrane but no...

journal_title：Leukemia & lymphoma

authors： de Totero D,Carbone A,Tazzari PL,Raspadori D,Ventura A,Reato G,Lauria F,Foa R

更新日期：1994-01-01 00:00:00

abstract：:Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis. This study retrospectively analyzed patients with AITL from a single institution in Taiwan, aiming to define the clinical features and prognostic factors. Patients with AITL treated at our instituti...

journal_title：Leukemia & lymphoma

authors： Lin HN,Liu CY,Hong YC,Pai JT,Yang CF,Yu YB,Hsiao LT,Chiou TJ,Liu JH,Gau JP,Tzeng CH,Chen PM

更新日期：2010-12-01 00:00:00

abstract：:We report the clinical features and outcome of 22 TLS-ERG+ leukemia patients (20 AML and 2 B-ALL). TLS-ERG was tightly associated with extramedullary disease (EMD), complex chromosome abnormalities, and high risk gene mutations including IKZF1, WT1, TET2, NOTCH2, and PHF6. The 6-month leukemia free survival (LFS) with...

journal_title：Leukemia & lymphoma

authors： Pan J,Zhang Y,Zhao YL,Yang JF,Zhang JP,Liu HX,Wu T,Tong CR

更新日期：2017-07-01 00:00:00

abstract：:Nearly ten years of research on the feasibility of specific immunotherapy targeting the junctional regions of BCR-ABL has considerably increased our knowledge of which MHC alleles might present BCR-ABL peptides, yet has failed to provide us with definite proof of appropriate processing of the hybrid oncoprotein into s...

journal_title：Leukemia & lymphoma

authors： Leeksma OC,Kessler JH,Huijbers IJ,Ten Bosch GJ,Melief CJ

更新日期：2000-06-01 00:00:00

abstract：:While more than 75% of the adult patients with acute lymphoblastic leukemia (ALL) achieve a complete remission after treatment with intensive chemotherapy, about 40% of them relapse within five years. These relapses are probably due to residual leukemic cells. Gene rearrangements are used as markers of clonality and t...

journal_title：Leukemia & lymphoma

authors： Knauf WU,Ho AD,Heger G,Hoelzer D,Hunstein W,Thiel E

更新日期：1991-01-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders of the elderly that carry an increased risk of progression to acute myeloid leukemia (AML). Since small non-coding RNAs (sRNAs), including microRNA (miRNAs), act as regulators of cellular differentiation, we hypothesized that changes to sRNAs might be ...

journal_title：Leukemia & lymphoma

authors： Guo Y,Strickland SA,Mohan S,Li S,Bosompem A,Vickers KC,Zhao S,Sheng Q,Kim AS

更新日期：2017-09-01 00:00:00

abstract：:The overall cure rate of adults with newly-diagnosed acute myelogenous leukemia (AML) treated with continuous infusion high-dose cytarabine (CIHDAC) is comparable to that with standard-dose ara-C plus anthracycline or amsacrine (AMSA). We tested whether the addition of AMSA to CIH-DAC improves the outcome of adults wi...

journal_title：Leukemia & lymphoma

authors： Ghaddar HM,Pierce S,Kantarjian HM,Freireich EJ,Keating MJ,Estey EH

更新日期：1996-06-01 00:00:00

abstract：:Bullous pyoderma gangrenosum begins as a bulla, nodule or nonulcerated erythematous plaque that blisters or ulcerates to form a superficial ulcer surrounded by a hemorrhagic, bullous border, which is surrounded by a blue-gray halo. Bullous pyoderma gangrenosum is most commonly associated with hematologic malignancies,...

journal_title：Leukemia & lymphoma

authors： Fox LP,Geyer AS,Husain S,Grossman ME

更新日期：2006-01-01 00:00:00